Personalis (NASDAQ:PSNL) Rating Increased to Hold at Wall Street Zen

Personalis (NASDAQ:PSNL) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Several other brokerages also recently weighed in on PSNL. BTIG Research lifted their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Guggenheim upped their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Morgan Stanley reduced their price objective on Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday. Finally, Needham & Company LLC increased their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Personalis Price Performance

Shares of PSNL opened at $7.84 on Friday. Personalis has a 12 month low of $2.83 and a 12 month high of $11.50. The stock has a fifty day moving average price of $8.85 and a 200 day moving average price of $8.12. The company has a market cap of $820.30 million, a P/E ratio of -8.62 and a beta of 2.02.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%.The company had revenue of $17.35 million for the quarter, compared to analysts’ expectations of $17.12 million. As a group, research analysts anticipate that Personalis will post -1.4 earnings per share for the current year.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares in the last quarter. Legal & General Group Plc bought a new stake in Personalis during the second quarter worth approximately $30,000. International Assets Investment Management LLC bought a new stake in Personalis during the fourth quarter worth approximately $31,000. Ameritas Investment Partners Inc. acquired a new stake in Personalis in the second quarter worth approximately $34,000. Finally, BNP Paribas Financial Markets lifted its position in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the period. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.